Pharsight

Drugs that contain Dolutegravir Sodium; Lamivudine

1. Dovato patents expiration

DOVATO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8129385 VIIV HLTHCARE Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness
Oct, 2027

(3 years from now)

US9242986 VIIV HLTHCARE Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
Dec, 2029

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8129385

(Pediatric)

VIIV HLTHCARE Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness
Apr, 2028

(3 years from now)

US9242986

(Pediatric)

VIIV HLTHCARE Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
Jun, 2030

(6 years from now)

US11234985 VIIV HLTHCARE Antiviral therapy
Jan, 2031

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Apr 08, 2022
New Indication(I-839) Aug 06, 2023

Market Authorisation Date: 08 April, 2019

Treatment: Treatment of hiv infection

Dosage: TABLET;ORAL

How can I launch a generic of DOVATO before it's drug patent expiration?
More Information on Dosage

DOVATO family patents

Family Patents